Drugs / Tacrolimus ointment
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05856994 | Sep 2024 → Dec 2027 expected | — | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tacrolimus ointment | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05856994 ↗ |
| Action | Inhibit | “Tacrolimus inhibits T-lymphocyte activation” NCT05856994 ↗ |
| Modality | Other / unclassified | “Protopic® (tacrolimus) Ointment is a macrolide immunosuppressant and a calcineurin inhibitor.” NCT05856994 ↗ |
| Route | Topical | “tacrolimus (0.03%) ointment will be applied over the burn” NCT05856994 ↗ |